These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36651339)

  • 21. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents.
    Hemetsberger R; Abdelghani M; Toelg R; Mankerious N; Allali A; Garcia-Garcia HM; Windecker S; Lefèvre T; Saito S; Slagboom T; Kandzari D; Koolen J; Waksman R; Richardt G
    J Am Heart Assoc; 2021 Jun; 10(12):e019815. PubMed ID: 34056911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions.
    Gallone G; D'Ascenzo F; Ielasi A; Landra F; Stefanini GG; Di Biasi M; Mancone M; Tomai F; Infantino V; Rognoni A; Briguori C; Boccuzzi G; Smolka G; Chiarito M; Capodanno D; Chieffo A; Fabbiocchi F; Poli A; Tespili M; D'Urbano M; Giordano A; Escaned J; De Ferrari GM; Sardella G
    Cardiovasc Revasc Med; 2022 Feb; 35():66-73. PubMed ID: 33903036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
    Vardi M; Burke DA; Bangalore S; Pencina MJ; Mauri L; Kandzari DE; Leon MB; Cutlip DE
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1031-8. PubMed ID: 23737390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial.
    Kim SH; Kang SH; Lee JM; Chung WY; Park JJ; Yoon CH; Suh JW; Cho YS; Doh JH; Cho JM; Bae JW; Youn TJ; Chae IH
    Catheter Cardiovasc Interv; 2020 Dec; 96(7):1399-1406. PubMed ID: 31859438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
    Kufner S; Joner M; Thannheimer A; Hoppmann P; Ibrahim T; Mayer K; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
    Circulation; 2019 Jan; 139(3):325-333. PubMed ID: 30586724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial.
    Romaguera R; Gómez-Hospital JA; Gomez-Lara J; Brugaletta S; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Montanya E; Fernandez-Ortiz A; Alfonso F; Valgimigli M; Sabate M; Cequier A
    JACC Cardiovasc Interv; 2016 Jan; 9(1):42-50. PubMed ID: 26762910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
    Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
    JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
    Kufner S; Sorges J; Mehilli J; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Rheude T; Ibrahim T; Massberg S; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):784-792. PubMed ID: 27017366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
    Patra S; Chakraborty RN; Pande A; Banerjee S; Jena M; Mandal PC; De SK; Khan A; Das SS; Ghosh D; Nag R
    Cardiovasc Revasc Med; 2017; 18(3):160-164. PubMed ID: 28017259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term (5-year) clinical evaluation of the Resolute zotarolimus-eluting coronary stent: The RESOLUTE US clinical trial.
    Kirtane AJ; Yeung AC; Ball M; Carr J; O'Shaughnessy C; Mauri L; Liu M; Leon MB
    Catheter Cardiovasc Interv; 2020 May; 95(6):1067-1073. PubMed ID: 31301219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
    Silber S; Serruys PW; Leon MB; Meredith IT; Windecker S; Neumann FJ; Belardi J; Widimsky P; Massaro J; Novack V; Yeung AC; Saito S; Mauri L
    JACC Cardiovasc Interv; 2013 Apr; 6(4):357-68. PubMed ID: 23523454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymer-Free vs. Polymer-Coated Drug-Eluting Stents for the Treatment of Coronary Artery Disease: A Meta-Analysis of 16 Randomized Trials.
    Verdoia M; Kedhi E; Suryapranata H; Galasso G; Dudek D; De Luca G
    Cardiovasc Revasc Med; 2020 Jun; 21(6):745-753. PubMed ID: 31669109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
    Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Baldetti L; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Reimers B; Fabbiocchi F; Bartorelli A; Colombo A; Godino C
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):255-265. PubMed ID: 31905259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.